发明公开
EP2661278A4 GENERATION OF ANTIBODIES TO TUMOR ANTIGENS AND GENERATION OF TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS
审中-公开
抗体肿瘤抗原的产生和生产由溶瘤病毒疫苗的管理肿瘤特异性补体依赖性细胞毒作用
- 专利标题： GENERATION OF ANTIBODIES TO TUMOR ANTIGENS AND GENERATION OF TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS
- 专利标题（中）： 抗体肿瘤抗原的产生和生产由溶瘤病毒疫苗的管理肿瘤特异性补体依赖性细胞毒作用
-
申请号： EP12732263申请日： 2012-01-04
-
公开(公告)号： EP2661278A4公开(公告)日： 2015-10-07
- 发明人: KIRN DAVID , BELL JOHN , BREITBACH CAROLINE , MOON ANNE , HWANG TAE-HO , LEE YU KYOUNG , KIM MI-KYUNG
- 申请人： SILLAJEN BIOTHERAPEUTICS INC , SILLAJEN INC
- 专利权人： SILLAJEN BIOTHERAPEUTICS INC,SILLAJEN INC
- 当前专利权人： SILLAJEN BIOTHERAPEUTICS INC,SILLAJEN INC
- 优先权： US201161429622 2011-01-04
- 主分类号： A61K35/76
- IPC分类号： A61K35/76 ; A61K39/12 ; A61P35/00 ; C07K16/30
摘要：
The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
信息查询
